[1]
|
朱筱旌, 谷昊, 马静瑶. 原发性免疫性血小板减少症患儿并发颅内出血: 单中心临床数据分析[J]. 血栓与止血学, 2020, 26(5): 721-724.
|
[2]
|
王丽媛, 刘亢亢, 储金华, 杨林海, 谢志伟, 张坤龙, 蔡华菊, 吴正玉, 王宁玲. 儿童免疫性血小板减少症病程慢性化影响因素的研究[J]. 中国实验血液学杂志, 2021, 29(3): 881-886.
|
[3]
|
中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版) [J]. 中华血液学杂志, 2020, 41(8): 617-623.
|
[4]
|
中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版) [J]. 中华儿科杂志, 2021, 59(10): 810-819.
|
[5]
|
Palandri, F., Polverelli, N., Catani, L., et al. (2014) The Choice of Second-Line Therapy in Steroid-Resistant Immune Thrombocytopenia: Role of Platelet Kinetics in a Sin-gle-Centre Long-Term Study. American Journal of Hematology, 89, 1047-1050. https://doi.org/10.1002/ajh.23823
|
[6]
|
Evim, M.S., Baytan, B. and Güneş, A.M. (2014) Childhood Immune Thrombocytopenia: Long-Term Follow-Up Data Evaluated by the Criteria of the International Working Group on Im-mune Thrombocytopenic Purpura. Turkish Journal of Haematology, 31, 32-39. https://doi.org/10.4274/Tjh.2012.0049
|
[7]
|
Neunert, C., Terrell, D.R., Arnold, D.M., et al. (2019) American Soci-ety of Hematology 2019 Guidelines for Immune Thrombocytopenia. Blood Advances, 3, 3829-3866. https://doi.org/10.1182/bloodadvances.2019000966
|
[8]
|
Provan, D., Arnold, D.M., Bussel, J.B., et al. (2019) Up-dated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia. Blood Advances, 3, 3780-3817.
https://doi.org/10.1182/bloodadvances.2019000812
|
[9]
|
Bussel, J.B., Cheng, G., Saleh, M.N., et al. (2007) El-trombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. The New England Journal of Medicine, 357, 2237-2247. https://doi.org/10.1056/NEJMoa073275
|
[10]
|
Bussel, J.B., de Miguel, P.G., Despotovic, J.M., et al. (2015) Eltrombopag for the Treatment of Children with Persistent and Chronic Immune Thrombocytopenia (PETIT): A Randomised, Multicentre, Placebo-Controlled Study. The Lancet Haematology, 2, e315-e325. https://doi.org/10.1016/S2352-3026(15)00114-3
|
[11]
|
Grainger, J.D., Locatelli, F., Chotsampancharoen, T., et al. (2015) Eltrombopag for Children with Chronic Immune Throm- bocytopenia (PETIT2): A Randomised, Multicentre, Placebo-Controlled Trial. The Lancet, 386, 1649-1658.
https://doi.org/10.1016/S0140-6736(15)61107-2
|
[12]
|
Zaja, F., Baccarani, M., Mazza, P., et al. (2010) Dexame-thasone plus Rituximab Yields Higher Sustained Response Rates than Dexamethasone Monotherapy in Adults with Pri-mary Immune Thrombocytopenia. Blood, 115, 2755-2762.
https://doi.org/10.1182/blood-2009-07-229815
|
[13]
|
Audia, S., Mahévas, M., Nivet, M., Ouandji, S., Ciudad, M. and Bonnotte, B. (2021) Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. Hemasphere, 5, e574. https://doi.org/10.1097/HS9.0000000000000574
|
[14]
|
Zufferey, A., Kapur, R. and Semple, J.W. (2017) Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). Journal of Clinical Medicine, 6, Article No. 16. https://doi.org/10.3390/jcm6020016
|
[15]
|
Li, Y., Shi, Y., He, Z., et al. (2019) The Efficacy and Safety of Low-Dose Rituximab in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Platelets, 30, 690-697. https://doi.org/10.1080/09537104.2019.1624706
|
[16]
|
朱筱旌, 马静瑶, 陈振萍, 谢幸娟, 张佳璐, 马洁, 姚佳峰, 张利强, 吴润晖. 两种小剂量利妥昔单抗二线治疗儿童原发性免疫性血小板减少症的效果及安全性比较[J]. 中华儿科杂志, 2022, 60(11): 1185-1190.
|
[17]
|
刘晓帆, 黄月婷, 陈云飞, 刘葳, 薛峰, 张磊, 杨仁池. 小剂量利妥昔单抗治疗儿童原发免疫性血小板减少症50例临床观察[J]. 中华血液学杂志, 2014, 35(12): 1079-1082.
|
[18]
|
Lucchini, E., Zaja, F. and Bussel, J. (2019) Rituximab in the Treatment of Immune Thrombocytopenia: What Is the Role of This Agent in 2019? Haematologica, 104, 1124-1135. https://doi.org/10.3324/haematol.2019.218883
|
[19]
|
Al-Habsi, K., Al-Khabori, M., Al-Muslahi, M., et al. (2015) Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia. Oman Medical Journal, 30, 111-114. https://doi.org/10.5001/omj.2015.24
|
[20]
|
Matsubara, K., Takahashi, Y., Hayakawa, A., et al. (2014) Long-Term Follow-Up of Children with Refractory Immune Thrombocytopenia Treated with Rituximab. International Journal of Hematology, 99, 429-436.
https://doi.org/10.1007/s12185-014-1541-y
|
[21]
|
朱筱旌, 马静瑶, 陈振萍, 谢幸娟, 张佳璐, 马洁, 姚佳峰, 张利强, 吴润晖. 小剂量利妥昔单抗二线治疗儿童原发性免疫性血小板减少症90例临床观察[J]. 中国小儿血液与肿瘤杂志, 2022, 27(6): 367-371, 389.
|
[22]
|
龙思琪, 马洁, 傅玲玲, 张利强, 马宏浩, 张蕊, 吴润晖. 儿童重症难治性免疫性血小板减少症应用小剂量利妥昔单抗联合大剂量地塞米松冲击治疗疗效及安全性——27例单中心数据分析[J]. 中国小儿血液与肿瘤杂志, 2018, 23(4): 205-210.
|
[23]
|
Arnold, D.M., Dentali, F., Crowther, M.A., et al. (2007) Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. Annals of Internal Medicine, 146, 25-33.
https://doi.org/10.7326/0003-4819-146-1-200701020-00006
|
[24]
|
Butler, T., Evangelista, M.L., Amadori, S., Newland, A.C. and Stasi, R. (2007) Activity and Safety Profile of Low- Dose Rituximab for the Treatment of Autoim-mune Cytopenias in Adults. Haematologica, 92, 1695-1698.
https://doi.org/10.3324/haematol.11709
|
[25]
|
Kapoor, R., Kumar, R., Mahapatra, M., Pati, H.P. and Pramanik, S.K. (2017) Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings. Indian Journal of Hematology and Blood Transfusion, 33, 568-573.
https://doi.org/10.1007/s12288-016-0764-x
|
[26]
|
Dong, Y., Yue, M. and Hu, M. (2021) The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. BioMed Research International, 2021, Article ID: 9992086. https://doi.org/10.1155/2021/9992086
|
[27]
|
Levy, R., Mahévas, M., Galicier, L., et al. (2014) Profound Symptomatic Hypogammaglobulinemia: A Rare Late Complication af-ter Rituximab Treatment for Immune Thrombocytopenia. Report of 3 Cases and Systematic Review of the Literature. Au-toimmunity Reviews, 13, 1055-1063. https://doi.org/10.1016/j.autrev.2014.08.036
|
[28]
|
Deshayes, S., Khellaf, M., Zarour, A., et al. (2019) Long-Term Safety and Efficacy of Rituximab in 248 Adults with Immune Thrombocytopenia: Results at 5 Years from the French Prospective Registry ITP-Ritux. American Journal of Hematology, 94, 1314-1324. https://doi.org/10.1002/ajh.25632
|